P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer
Citations Over TimeTop 10% of 2016 papers
Abstract
Autocrine VEGF signaling is critical for sustaining prostate and other cancer stem cells (CSCs), and it is a potential therapeutic target, but we observed that CSCs isolated from prostate tumors are resistant to anti-VEGF (bevacizumab) and anti-VEGFR (sunitinib) therapy. Intriguingly, resistance is mediated by VEGF/neuropilin signaling, which is not inhibited by bevacizumab and sunitinib, and it involves the induction of P-Rex1, a Rac GEF, and consequent Rac1-mediated ERK activation. This induction of P-Rex1 is dependent on Myc. CSCs isolated from the PTEN(pc-/-) transgenic model of prostate cancer exhibit Rac1-dependent resistance to bevacizumab. Rac1 inhibition or P-Rex1 downregulation increases the sensitivity of prostate tumors to bevacizumab. These data reveal that prostate tumors harbor cells with stem cell properties that are resistant to inhibitors of VEGF/VEGFR signaling. Combining the use of available VEGF/VEGFR-targeted therapies with P-Rex1 or Rac1 inhibition should improve the efficacy of these therapies significantly.
Related Papers
- → Sunitinib resistance in renal cell carcinoma(2014)70 cited
- Molecular mechanisms of sunitinib resistance in renal cell carcinoma(2014)
- The clinical characteristics of hypothyroidism after sunitinib treatment in a Korean population(2009)
- → Abstract 1377: Characterisation of mechanisms of resistance to sunitinib in a unique pre-clinical RCC model(2012)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)